Preview

Научно-практическая ревматология

Расширенный поиск

Перспективы улучшения качества жизни больных ревматоидным артритом при применении полностью человеческих моноклональных антител к фактору некроза опухоли альфа

https://doi.org/10.14412/1995-4484-2008-659

Полный текст:

Об авторе

V N. Amirdjanova



Список литературы

1. <div><p>Sacks J.J., Helmick C.G., Langmaicl G. Deaths from arthritis and other rheumatic conditionts, United states, 1979-1998. J. Rheumatol.,2004,31,1823-1828</p><p>Lee D.M.,Weinblatt M.E. Rheumatoid arthritis. Lancet,2001,358,903-911</p><p>Uhlig Т., Haavardsholm E.A.,Kvien Т.К. Comparison of the HAQ and the modified HAQ-DI ( MHAQ) in patients with rheumatoid arthritis. Rheumatology (Oxford),2006,45,454-458</p><p>Tugwell P., Wells G., Strand V. et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with metotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month placebo- controlled trial. Leflunomide Rheumatoid Arthritis Investigator Group. Arthr. Rheum.,2000,43,506-514</p><p>Амирджанова В.H.,Минимально-значимые клинические изменения показателей качества жизни и оценка эффективности терапии. Научно- практич. ревматол., 2007,5, 70-76</p><p>Strand V., Pincus Т. The HAQ provides a single effective measure to discriminate active from placebo treatment in randomized controlled trials in rheumatoid arthritis. Arthr. Rheum.,2003,48,3656, abstr. LB 6</p><p>Kosinski М., Zhao S.Z., Dedhiya S. etal. Determining minimally important changes in generic and disease- specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthr. Rheum.,2000,43,14 78-14-87</p><p>Strand V., Bombardier C., Maetzel A. et al. Use of minimum clinically important differences [MCID] in evaluating patient responsesto treatment of RA. Arthr. Rheum., 2001,44(suppl),S187</p><p>Scott D.L., Pugner K., Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford),2000,39,122-132</p><p>Scott D.L.,Smith C., Kingsley G. Joint damade and disability in rheumatoid arthritis: an updated systematic review. Clin. Exper. Rheumatol., 2003,21 (suppl. 31) S20-S27</p><p>Pollard L., Choy E.H.,Scott D.L. The consequences of rheumatoid arthritis.quality of life measures in the individual patient. Clin.Exp.Rheumatol.,2005,23 (suppl. 39) S43-S52</p><p>Амирджанова B.H., Горячев Д.В., Ребров А.П и соав. Популяционные показатели качества жизни по данным многоцентрового исследования качества жизни больных ревматоидным артритом (МИРАЖ) Научно-практич. ревматол., 2008, 1, 36-48</p><p>West Т., Jonsson S.W. yeakth-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-tern disease and controls, using SF-36. Clin. Rheumatol.,2005,24,117-122</p><p>Strand V.,Cohen S.,Crawford B. et al. for the Leflunomide Investigators Group. Patient-reported outcome better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford),2004,43,640-647</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et a I Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthr.Rheum., 2003,48,35-45</p><p>Torrance G.W., Tugwell P., Amorosi S. et al. Imrpovement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford), 2004,43,712-718</p><p>Van de Putte L., Atkins C.,Malaise M. et al. Sustained 5-year efficacy of adalimumab (HUMIRA) monotherapy in DMARD-refractory rheumatoid arthritis (RA). Arthr.; Rheum., 2003, 48, 9, suppl. (S314).</p><p>Strand V. et al. Adalimumab improves Health-related Quality of life in rheumatoid arthritis patients. EULAR, 2003, 'SAT 0246</p><p>Breedveld F.C., Weisman M.N., Kavanaugh A.F. et at. The RPEMIER Study. A multicenter, randomized, double-blind clinical study of combination therapy with adalimumab and methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not previous methotrexate therapy. Arthr.Rheum., 2006,54,26-37</p><p>Burmester G. R., et al. Adalimumab effective and safe in treating RA in real life clinical practice: Final summary of the 6610 patients in REACT study. EULAR 2006, Amsterdam, THU0213</p><p>Kimel, Mary Cifaldi et al. Adalimumab plus Methotrexate Improved SF-36 Scores and Reduced the Effect of Rheumatoid Arthritis (RA) on Work Activity for Patients with Early RA. J.Rheumatol., 2008, 35, 2, 2008.</p><p>Bejarano V. et al. Improved work stability and reduced job loss with adalimumab plus methotrexate in early rheumatoid arthritis: Results of the prevention of work disability (PROWD) study. Ann. Rheum. Dis., 2007, 2(176), THU0167.</p></div><br />


Для цитирования:


Amirdjanova V.N. Перспективы улучшения качества жизни больных ревматоидным артритом при применении полностью человеческих моноклональных антител к фактору некроза опухоли альфа. Научно-практическая ревматология. 2008;46(3):49-53. https://doi.org/10.14412/1995-4484-2008-659

For citation:


Amirdjanova V.N. Perspectives of Quality of Life improvement in patients with rheumatoid arthritis with administration of fully human anti-tumor necrosis factor alpha monoclonal antibodies. Rheumatology Science and Practice. 2008;46(3):49-53. (In Russ.) https://doi.org/10.14412/1995-4484-2008-659

Просмотров: 378


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)